Polar Peptides, a Canadian seller of research peptides, now markets alcohol wipes as sterile preparation supplies and has formalized reconstitution and storage guidance for lyophilized peptides: 2 mL of bacteriostatic water, gentle mixing, and refrigeration at 2 to 8°C. The company claims to be…
Polar Peptides, a Canadian seller of research peptides, now markets alcohol wipes as sterile preparation supplies for peptide reconstitution and claims to be Canada's only domestic premium peptide manufacturer. The company's product page, current as of May 12, 2026, positions the wipes as pre-injection antiseptic wipes used to clean skin and vial tops before peptide injections to maintain sterility and reduce infection risk. The same page formalizes the company's reconstitution and storage guidance for lyophilized peptides and asserts a distinction between true domestic manufacturing in Canada and products that are merely shipped from Canada.
The catalog covered by the page includes alcohol wipes, bacteriostatic water as a reconstitution diluent in a standard 2 mL per vial format, an online peptide calculator for concentration and preparation calculations, lyophilized research peptides, peptide blends, laboratory-use compounds, and analytical materials. All peptides are supplied in lyophilized form. Orders are stated to ship from a Canadian fulfillment centre within 24 hours, Monday through Friday, with delivery typically taking 2 to 5 business days depending on location and the shipping method selected.
The new positioning is notable less for the product itself than for what it formalizes. Alcohol wipes are a commodity item. By placing them in an explicit preparation workflow alongside bacteriostatic water and a peptide calculator, the company is standardizing a procedure that most sellers of lyophilized research peptides leave implicit: how to take a freeze-dried vial from storage to injection-ready solution without contamination or damage to the peptide. The page also makes a manufacturing claim that, if true, would set the company apart in a market where import and distribution are more common than production.
The page lists syringe formats among its peptide supplies, including 1 ml insulin syringes and 29g syringes. Its peptide range includes products identified by amino acid length designations: HGH fragment 176-191, full-length HGH 191aa, Follistatin 344, and Follistatin 315. The numeric labels matter to researchers because they identify exactly which variant of a given peptide a vial contains, and variant identity is a core determinant of experimental design and results.
The central claim is about domestic production. Polar Peptides says it is Canada's only domestic manufacturer and supplier of premium research peptides, with production and fulfillment handled in Canada. The company argues that a domestic process allows closer oversight of quality, consistency, packaging, and labeled vial weight compared with sellers that rely on imported vials. It states that many companies ship from Canada while still sourcing finished vials from overseas, and it distinguishes itself as focused on true domestic manufacturing. The exclusivity claim functions as a marketing differentiator in a market where buyers cannot easily inspect production facilities, which is precisely why it demands verification rather than acceptance.
The small-print terms complete the picture. Free shipping is applied automatically at checkout for orders of $300 or more, a threshold that functions as a de facto minimum order for small laboratories consolidating supplies. Customer support is stated to be available 24/7. None of these terms addresses the question that matters most to a buyer: what evidence exists that the product in the vial matches its label.
The formalized protocol is straightforward. Most standard lyophilized research vials are prepared using 2 mL of bacteriostatic water unless otherwise specified on the product page or vial label. The water should be added slowly down the inside wall of the vial, followed by gentle swirling or rolling, and aggressive shaking should be avoided. Prepared peptide vials should typically be stored refrigerated between 2 to 8°C. Unreconstituted vials should be kept in a cool, dry environment away from direct sunlight, moisture, and excessive heat.
The "unless otherwise specified" clause is important. Two milliliters is a convention, not a universal. Different peptides, vial fill weights, and study designs require different diluent volumes to reach a target concentration. A laboratory that treats 2 mL as a fixed rule rather than a default risks preparing concentrations that do not match its protocol. The presence of the calculator suggests the company expects customers to vary volumes, but the page does not document the calculator's assumptions.
The relationship between diluent volume and concentration is the actual subject of the protocol. For a given vial, the concentration of the prepared solution is the fill weight divided by the diluent volume, so any change in volume changes concentration directly. Accurate preparation also requires knowing what the labeled weight represents. Product labels typically state gross fill, which includes peptide, residual water, salts, and counterions such as trifluoroacetate carried over from HPLC purification. Polar Peptides claims oversight of labeled vial weight, but it does not state whether the labeled figure refers to gross fill or net peptide content, and it does not describe the verification method.
The protocol's logic follows from the chemistry of peptides in solution. Peptides are short chains of amino acids that act as signaling molecules involved in tissue repair, immune response, and cellular communication. In aqueous solution, they are subject to hydrolysis, deamidation, oxidation, and microbial growth, all of which degrade activity over time. Lyophilization, or freeze-drying, removes water and slows those reactions, which is why the company supplies all peptides in lyophilized form for long-term stability.
Reconstitution reverses the process, and the recommended technique addresses two failure modes. Directing the diluent down the inside wall of the vial rather than onto the lyophilized cake prevents localized shearing and foaming. Aggressive shaking creates air-water interfaces and mechanical stress, which can denature peptides and promote aggregation, producing particulates and reducing the effective concentration. Gentle swirling or rolling mixes without those stresses.
Bacteriostatic water is not plain water. It contains a preservative, typically benzyl alcohol, that inhibits bacterial growth during multi-use storage, which is why the company designates a 2 mL per vial standard for a diluent intended to be drawn from more than once. The designation of bacteriostatic water as a reconstitution diluent rather than a solvent matters as well: the goal is to restore the peptide to solution for use, not to alter its chemical form, and a standardized diluent volume is the simplest way to keep concentration calculations consistent across a laboratory. Refrigeration at 2 to 8°C further slows hydrolytic and microbial degradation of the prepared solution. For unreconstituted vials, the instruction to store cool and dry, away from direct sunlight and excessive heat, protects the lyophilized cake from moisture uptake and thermal degradation before the vial is opened.
The catalog's variant designations reflect the same concern with molecular identity. HGH 191aa is the full-length human growth hormone chain of 191 amino acids. HGH fragment 176-191 is the C-terminal portion spanning residues 176 to 191, studied in research settings separately from the full-length hormone. Follistatin 344 and Follistatin 315 denote different variant lengths of follistatin, a protein that binds and neutralizes activin and other members of the TGF-beta superfamily. For a laboratory, specifying the exact variant is a precondition for interpretable and reproducible results.
The clinical record for unapproved research peptides and the record for approved peptide drugs diverge sharply, and Peptide Atlas' own files show the gap. CJC-1295, a growth hormone releasing hormone analog, has 0 registered clinical trials on file at Peptide Atlas and 7 indexed PubMed papers. Its recent literature is dominated by detection and control work. PMID 41880199, published in the Journal of Sports Medicine and Physical Fitness on 2026-03-25, is a critical review of peptide and peptide-analog drug use in sport and bodybuilding. PMID 41138283, published in the Journal of Pharmaceutical and Biomedical Analysis on 2026-01-15, describes analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. PMID 41490200, published in JAAOS Global Research and Reviews on 2026-01-02, reviews therapeutic peptides in orthopaedics. PMID 41476424, published in the American Journal of Sports Medicine on 2026-01-01, is a primer on injectable peptide therapy for orthopaedic and sports medicine physicians. PMID 30938069, published in Drug Testing and Analysis on 2019-08-01, reports a method for confirming CJC-1295 abuse in equine plasma by LC-MS/MS. The theme running through that literature is not therapeutic efficacy. It is detection of use. The analytical work is also a reminder that these molecules are monitored in sport and in animals, and that the same compounds sold as laboratory reagents are the subject of active detection method development.
Semaglutide sits at the other end of the same market. Peptide Atlas has 668 registered clinical trials for semaglutide on file, with a phase breakdown of Phase 2: 4, Phase 4: 4, and Phase 3: 1, and 10 trials currently recruiting. Named trials include NCT07586150 LIFETRAIN , a personalized pharmaco-lifestyle intervention for severe mental illness; NCT07430332, a Phase 2 trial of a GLP-1 receptor agonist in Stage 1 Type 1 Diabetes; NCT07614412 SHIELD-T1D , a Phase 2 trial of Shingrix and a GLP-1 agonist for beta-cell preservation in recent-onset Type 1 Diabetes; NCT07462663 SHAPE-ENDO , a Phase 4 trial of pre-surgical optimization in patients with obesity and early-stage endometrial cancer; NCT07027969, a Phase 4 trial of metabolic surgery for atrial fibrillation elimination; and NCT06977438, a Phase 4 trial of a GLP-1 plus lifestyle program for childhood obesity. Peptide Atlas indexes 197 PubMed papers on semaglutide, and its file includes 8 third-party lab purity tests with the highest observed purity at 99.979%.
The two cases frame the regulatory gap that makes a company like Polar Peptides possible. Semaglutide is a regulated pharmaceutical with hundreds of trials and documented purity data. CJC-1295 is a research chemical with zero clinical trials and a literature centered on anti-doping analysis. Both are peptides. The difference is approval status, and the Polar Peptides page identifies no Canadian regulatory framework attached to the sale of unapproved research peptides.
For a laboratory buyer, the distinction between a company that manufactures domestically and one that merely ships from Canada is not cosmetic. Peptide quality is determined by synthesis, purification, and fill, all of which happen before shipping. A seller importing finished vials has little control over the first three links in that chain. A domestic manufacturer can, in principle, control synthesis conditions, purification, fill accuracy, and labeled vial weight, which is the amount of peptide actually present in each vial.
The claim of closer oversight of labeled vial weight is particularly relevant to research. Vial-to-vial consistency is a precondition for reproducible dosing in animal studies and for accurate concentration calculations. If a vial's label and its contents…
Peptides referenced: Semaglutide, CJC-1295, Follistatin 344, HGH Fragment 176-191, Growth Hormone, HGH 191AA, Follistatin, GLP-1.
Vendors referenced: Polar Peptides.
Related reading: Bacteriostatic Water Shelf Life After Opening: Refrigeration Guide, Online Healthcare Treatments in British Columbia, GHK-Cu Peptide: Key Mechanisms and Research Findings, BPC-157 vs GHK-Cu: Comparing Top Research Peptides.